Who invented tesamorelin? Scientists at Theratechnologies, a biotechnology company in Montreal, discovered it in 1995. The company's own history dates its discovery to that year. The work began with a practical problem: making a more stable version of a hormone signal the body already uses.
Who invented tesamorelin, and what were they changing?
The starting point was growth hormone-releasing hormone, or GHRH. This natural messenger tells the pituitary, a small gland below the brain, to release growth hormone. Our account of who discovered GHRH follows that earlier work.
Tesamorelin is an analog, meaning a modified copy, of that messenger. The challenge was that enzymes, proteins that break molecules apart, quickly cut up natural GHRH in blood. A useful drug candidate needed to resist that breakdown while still delivering the signal.
That is the development work behind tesamorelin. The Montreal team kept the natural hormone's full chain and changed one end. The chemical change, the first human tests and the later brand authorization were separate steps across many years.
From TH9507 to tesamorelin
TH9507 was the development code used in early studies. Tesamorelin became the medicine's nonbrand name; Egrifta is a brand name for a specific product. The National Library of Medicine's naming record connects all three names, including the spelling TH-9507.
Those names help when reading older papers. A trial that calls the compound TH9507 can belong to the tesamorelin program. The code itself does not give the date of the first discovery or identify a different medicine.
Tesamorelin’s N-terminal change: a cap at the front
Tesamorelin keeps GHRH's chain of 44 amino acids, the building blocks of proteins. The Egrifta WR label describes an added hexenoyl group at its N-terminal end, meaning the front of that chain. That small chemical group contains six carbon atoms.
The original Food and Drug Administration (FDA) review describes how this addition increases resistance to breakdown in human blood. It helps explain the word “stabilized” in descriptions of tesamorelin. The molecule still carries a GHRH signal; it does not supply growth hormone itself.
The first human studies came before the 2005 paper
FDA identifies a study called TCHUV 10-98 as the first human study. Its tables place it in Switzerland in 1999, with six healthy men. Researchers tested single doses and measured hormone responses and how the compound moved through the body.
The same review lists a seven-day study in healthy volunteers in Canada in 2001. These were early development studies. FDA also cautioned that the early blood-testing method could pick up broken pieces of the molecule, making those measurements preliminary.
Then came the 2005 AIDS paper by Julian Falutz and colleagues. Falutz was based at Montreal General Hospital, part of McGill University Health Center. This trial enrolled 61 adults with HIV and excess abdominal fat for 12 weeks. HIV is a virus that weakens the immune system.
The 2005 publication documents a later clinical step. It is not the date tesamorelin was invented, and it was not the first time people received it.
Why the program measured IGF-1
IGF-1, short for insulin-like growth factor 1, is a growth signal made mainly by the liver in response to growth hormone. Measuring it helped researchers ask whether the modified messenger was reaching the body's hormone system.
The 2005 study measured IGF-1 alongside body-fat changes and safety. A hormone response and a change in abdominal fat answer different questions, so both needed measurement.
That distinction still matters when reading IGF-1 levels by age. A higher result is not automatically a better result. Age and the laboratory's reference range help put the number in context.
From early trials to Egrifta
The program grew into larger trials in adults with HIV and lipodystrophy, a change in where the body stores fat. A 2007 New England Journal of Medicine paper, again led by Falutz, reported a trial of 412 adults over 26 weeks. It measured visceral fat, the fat deep around abdominal organs, using CT scans, which take detailed X-ray pictures.
These studies addressed a particular medical problem. They were not general weight-loss studies, and they did not establish results for everyone interested in body composition.
FDA's Egrifta record gives November 10, 2010 as the original approval date. Fifteen years separate the company's discovery date from that milestone. Discovery supplied a candidate; human studies and regulatory review determined a particular product's labeled use.
Where tesamorelin stands today
As of November 12, 2026, the day this article was written, the current Egrifta WR prescribing information carries “Revised: 3/2025.” Its use remains reducing excess abdominal fat in adults with HIV and lipodystrophy; it is not indicated for weight-loss management.
HHS, the Department of Health and Human Services, published an October 30 notice of a draft peptide-compounding policy. Its Appendix A lists six peptides; tesamorelin is not among them. Our HHS peptide-policy explainer covers the document's conditions.
Development continues beyond the original use. As of November 12, 2026, the day this article was written, a Johns Hopkins trial record updated November 9 lists a recruiting study after surgical repair of an arm nerve. It has no posted results. That update documents ongoing testing, not evidence that tesamorelin repairs nerves.
The prescription route now
Tesamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Egrifta's product history does not establish the same clinical results for a compounded preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
The brand label contraindicates use, meaning it must not be used, during pregnancy, with active cancer, certain pituitary-system problems or an ingredient allergy. It also calls for monitoring blood sugar and IGF-1. Those safety questions belong in the clinical conversation.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescriber sets the treatment and monitoring plan based on the person's history, medicines and reason for considering treatment.





